{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"This analysis was planned but not performed for Part C as the study was terminated early during Part B.","groups":[{"description":"Participants were planned to receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.","id":"OG000","title":"Part C: GSK3039294"}],"populationDescription":"PK population. Data was not collected as study was terminated due to safety reasons during conduct of Part B (end of Cohort 3) whereas Part C was not initiated.","reportingStatus":"POSTED","timeFrame":"Day 1 (pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose); Day 2 to 20 (pre-dose); Day 21 (pre-dose, and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose; Week 4 and 5","title":"Part C: Time to Repletion of SAP","type":"SECONDARY"}